Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | TTR | P02766 | 4/20 | 0.65 |
| ▸ | ALB | P02768 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20626197 | 0.83 | TTR (0.59) | HSD17B10LMNANPSR1HTTTTR | |
| SCHEMBL17507483 | 0.79 | TTR (0.55) | HSD17B10LMNANPSR1HTTTTR | |
| SCHEMBL21378623 | 0.79 | TTR (1.00) | HSD17B10LMNAHTTTTRALB | |
| SCHEMBL17525273 | 0.79 | TTR (0.76) | HSD17B10LMNAHTTTTRALB | |
| SCHEMBL17525272 | 0.79 | TTR (0.83) | HSD17B10LMNAHTTTTRALB | |
| SCHEMBL17522782 | 0.79 | TTR (0.62) | HSD17B10LMNANPSR1HTTTTR | |
| SCHEMBL9803295 | 0.78 | KMT2A (0.80) | KMT2APLA2G4B | |
| Acoramidis SCHEMBL20475239 | 0.78 | TTR (0.98) | HSD17B10LMNAHTTTTRALB | |
| SCHEMBL4509654 | 0.77 | KMT2A (0.77) | KMT2APLA2G4B | |
| SCHEMBL19801753 | 0.77 | HSD17B10 (0.70) | HSD17B10LMNANPSR1HTTTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11129902-B2 | Enhanced SN-38 anticancer agent | Alhamadsheh, Mamoun M. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | Alhamadsheh, Mamoun M. (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3179857-B1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | ALHAMADSHEH MAMOUN M (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3179857-B1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | ALHAMADSHEH MAMOUN M (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20200384117-A1 | ENHANCED SN-38 ANTICANCER AGENT | MAHA THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200384117-A1 | ENHANCED SN-38 ANTICANCER AGENT | MAHA THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10772967-B2 | Enhanced anticancer agent | Alhamadsheh, Mamoun M. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10772967-B2 | Enhanced anticancer agent | Alhamadsheh, Mamoun M. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200179525-A1 | ENHANCED ANTICANCER AGENT | MAHA THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20200179525-A1 | ENHANCED ANTICANCER AGENT | MAHA THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-10172959-B2 | Systems for stabilizing and delivering active agents | Alhamadsheh, Mamoun M. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172959-B2 | Systems for stabilizing and delivering active agents | Alhamadsheh, Mamoun M. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180021446-A1 | SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS | MAHA THERAPEUTICS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180021446-A1 | SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS | MAHA THERAPEUTICS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180021446-A1 | SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS | MAHA THERAPEUTICS, INC. | 2018-01-25 | — | — | US | disclosed |
| EP-3179857-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | Alhamadsheh, Mamoun, M. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | MAHA THERAPEUTICS, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | MAHA THERAPEUTICS, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | MAHA THERAPEUTICS, INC. | 2016-02-18 | — | — | US | disclosed |
| WO-2016025129-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | ALHAMADSHEH MAMOUN M (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172959-B2 | Systems for stabilizing and delivering active agents | SERPINA6, SERPINC1, SERPINE1 | HSD17B10 3839/4885LMNA 991/4885NPSR1 1044/4885 |
| US-20180021446-A1 | SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS | SERPINA6, SERPINC1, SERPINE1 | HSD17B10 3839/4885LMNA 991/4885NPSR1 1044/4885 |
| US-20200384117-A1 | ENHANCED SN-38 ANTICANCER AGENT | LENG8, TSG101, CD47 | HSD17B10 4597/4885LMNA 2269/4885NPSR1 1018/4885 |
| US-20200179525-A1 | ENHANCED ANTICANCER AGENT | SERPINA6, HDGF, SERPINA3 | HSD17B10 4242/4885LMNA 1724/4885NPSR1 1822/4885 |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | LENG8, TSG101, CD47 | HSD17B10 4597/4885LMNA 2269/4885NPSR1 1018/4885 |
| US-10772967-B2 | Enhanced anticancer agent | SERPINA6, HDGF, SERPINA3 | HSD17B10 4242/4885LMNA 1724/4885NPSR1 1822/4885 |
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | TTR, TTPA, SERPINA6 | HSD17B10 2253/4885LMNA 1031/4885NPSR1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.